Can you provide dosing, indications, contraindications, pregnancy considerations, and side effects for Movantik (lubiprostone)?

Movantik (Naloxegol) - Clinical Overview

Important Note: The evidence provided discusses lubiprostone, NOT Movantik (naloxegol). Movantik is a peripherally-acting mu-opioid receptor antagonist (PAMORA) used specifically for opioid-induced constipation, while lubiprostone is an intestinal secretagogue used for chronic idiopathic constipation and IBS-C. I will provide information on Movantik based on the FDA label evidence and guideline recommendations for PAMORAs.

Indications

Movantik is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain 1. This is a second-line agent used when traditional laxatives fail to provide adequate relief 2.

Dosing

Standard Adult Dose

• 25 mg once daily in the morning 1
• Take on an empty stomach at least 1 hour before the first meal of the day or 2 hours after the meal 1

Dose Adjustments

Renal Impairment:

• Patients with creatinine clearance <60 mL/min: Reduce dose to 12.5 mg once daily 1
• Monitor closely for adverse reactions 1

Drug Interactions:

• When used with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): Reduce dose to 12.5 mg once daily 1
• Avoid grapefruit or grapefruit juice during treatment 1

Hepatic Impairment:

• No dose adjustment needed for mild to moderate hepatic impairment 1
• Use caution in severe hepatic impairment 1

Contraindications

Movantik is absolutely contraindicated in patients with:

• Known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction 1
• History of serious or severe hypersensitivity reaction to naloxegol 1

This is critical because PAMORAs can precipitate perforation in patients with occult GI obstruction.

Warnings and Precautions

Opioid Withdrawal

Risk of precipitating opioid withdrawal symptoms including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, and yawning 1. This occurs because naloxegol blocks peripheral opioid receptors. Patients maintained on methadone may be at higher risk.

Severe Abdominal Pain and/or Diarrhea

Monitor patients for development of severe, persistent, or worsening abdominal pain; discontinue if this occurs 1. Diarrhea is common and can be severe enough to require discontinuation.

Gastrointestinal Perforation

Cases have been reported, particularly in patients with conditions that may compromise GI wall integrity (e.g., peptic ulcer disease, diverticular disease, infiltrative GI malignancies, peritoneal metastases) 1.

Pregnancy and Lactation

Pregnancy Category: Not formally categorized under old system; limited human data available 1

• May precipitate opioid withdrawal in a fetus due to immature blood-brain barrier
• Use only if benefit justifies potential risk to fetus 1

Lactation:

• Unknown if naloxegol is excreted in human milk 1
• Consider developmental and health benefits of breastfeeding along with mother's clinical need and potential adverse effects on infant 1

Adverse Effects

Most Common (≥3% and greater than placebo):

• Abdominal pain (12-21% vs 7% placebo) 1
• Diarrhea (9-19% vs 5% placebo) 1
• Nausea (7-8% vs 5% placebo) 1
• Flatulence (6% vs 3% placebo) 1
• Headache (4% vs 3% placebo) 1

Serious Adverse Effects:

• Gastrointestinal perforation (rare but serious) 1
• Opioid withdrawal syndrome 1

Clinical Context from Guidelines

The 2019 AGA guideline strongly recommends naloxegol for laxative-refractory OIC with moderate quality evidence 2. The guideline emphasizes:

• Traditional laxatives should be first-line therapy for OIC (strong recommendation) 2
• PAMORAs like naloxegol are reserved for patients who fail laxative therapy 2
• Naloxegol has demonstrated efficacy in improving bowel movement frequency without compromising analgesia 2

Key Clinical Pearls:

• Always ensure patient has tried and failed traditional laxatives (PEG, stimulant laxatives) before initiating Movantik 2
• Screen for GI obstruction risk before prescribing - this is the most critical safety consideration 1
• Timing matters: Empty stomach dosing is essential for optimal absorption 1
• Monitor for withdrawal: Even though naloxegol doesn't cross blood-brain barrier significantly, peripheral withdrawal can occur 1
• Adjust for renal function and drug interactions: This prevents excessive exposure and adverse effects 1